# A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06874335/  
OnCo record `nct06874335` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of BHV-1530 run by Biohaven Therapeutics Ltd., now recruiting.

## Summary

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT06874335 by Biohaven Therapeutics Ltd., with 140 participants planned, started 2025-03-20, primary completion expected 2029-03. Conditions recorded: Solid Tumor. Interventions recorded: BHV-1530, Cemiplimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06874335
- Phase: 1
- Setting: A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination With Other Anti-Cancer Agents in Adult Participants With Advanced or Metastatic Solid Tumors
- Sponsor: Biohaven Therapeutics Ltd.
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT06874335: https://clinicaltrials.gov/study/NCT06874335

## Connected records

- drugs: [BHV-1530](https://onco.cc/drugs/bhv-1530/)
- companies: [Biohaven](https://onco.cc/companies/biohaven/)

---
JSON: https://onco.cc/api/v1/entities/nct06874335.json